medigraphic.com
Academia Mexicana de Neurología, A.C.

2011, Number 3

<< Back Next >>

Rev Mex Neuroci 2011; 12 (3)

Unusual clinical presentation of the Syndrome of Guillain-Barré

Ferrer Y, Hernández A, Olmedo F, Muñoz CD, Noguera O, Oliva M, Moreau N

Language: Spanish
References: 30
Page: 134-140
PDF size: 169.83 Kb.


ABSTRACT

The Guillain-Barré Syndrome is one Poligangliorradiculoneuropatía inflammatory acute of progressive and autoimmune character, that shows a classical introduction way characterized by progressive, symmetrical and upward muscular weakness. The intention of this investigation is to determine the f requency of the Guillain-Barré Syndrome with unusual clinical introduction in patients that came in the University Clinic of Maracaibo in the period 2005- 2008. Descriptive type study, prospective and longitudinal. The town was constituted by 25 patients with diagnosis of syndrome admitted to the institution; 20 patients were part of the study for demonstrating unusual clinical introduction, that is, fast beginning, asymmetrical and non upward progression of the paralysis motorboat. Clasificanon in 5 clinical groups, in view of the beginning and progression of the deficit motor sports. Every group was related to the progression of the paralysis and evolution; 35% of the patients initiated with motor sports deficit: Monoparesia brachial right spreading to brachial left-hand, crural right and left. 30% initiated with monoparesia brachial left-hand with area to brachial right, crural left-hand and right. 25 initiated% with monoparesia crural: 3 right spreading to brachial right, crural left, brachial left; 2 crural left-hand, that moved forward towards crural right, brachial right and left. 15% beginning with hemiparesia right. All received Immunoglobulin endovenosa, physical and rehabilitation therapy. 70% of patients evolved satisfactorily. Electromyography is practiced and his results alteration of the driving motorboat and denervation diffuse with a mortality located at 10%. In conclusion, the unusual clinical introduction of the illness is frequent in our middle in spite of the few details brought in the world medical literature.


REFERENCES

  1. Guillain G, Barré J, Strohl A. Sur a syndrome de radiculonévrite avec hyeralbuminose du liquide céphalorachidien sans réaction celulaire: remarques sur les caracters cliniques et graphiques des réflexes tendineux. Bull Soc Med Hop Paris 1916; 40: 146-270.

  2. Paulson G. The Landry Guillain Barré Sthrol syndrome in childhood. Dev Med Child Neurol 1970; 12: 6047.

  3. Fujil H, Kondo T, Yasuda K, Hiralzumi Y, Yamazaki M, Yuki M. An acute axonza form of Guillain-Barré syndrome with autoantibody against ganglioside GD1b: A case report. No-To-Hattatsu 1999; 25: 379-84.

  4. Pascual-Pascual S. Aspectos actuales de las neuropatías inflamatorias agudas y crónicas. Síndrome de Guillain-Barré y polineuritis crónica inflamatoria desmielinizante. Rev Neurol 2002; 35: 269-76.

  5. Lestayo-O’Farrill Z, Hernández-Cáceres J. Análisis del comportamiento del síndrome de Guillain-Barré. Consensos y discrepancias. Rev Neurol 2008; 46: 230-7.

  6. Midroni G, Bilbao J. The inflammatory demyelinating neuropathies. In: Midroni G, Bilbao JM (eds.). Biopsy diagnosis of peripheral neuropathy. Boston, Oxford, Melbourne: Butterworth-Heinemann; 1995, p. 153- 95.

  7. Hahn AF. Guillain Barré syndrome. Lancet 1998; 3: 526-541.

  8. Hund E, Borrel C, Cornblath D, Hanley D, Mackhann G. Intensive management and treatment of severe Guillaín-Barré syndrome. Crit Care Med 1999; 21: 105-11.

  9. Ropper A. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130-6.

  10. Lawn N, Elco F, Wijdicks M. Fatal Guillain-Barré syndrome. Neurology 1999; 52: 635-8.

  11. Asbury, AK, Cornblath, DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27(Suppl.): S21.

  12. Van der Meché F, Schmitz P. A randomized trial comparing intravenousimmune globulin and plasma exchange in Guillain-Barré syndrome Dutch Guillain-Barré Study Group. N Engl J Med 1992; 326: 1123-9.

  13. Willison H, Halstead S, Beveridge E, Zitman F, Greenshields K, Morgan B, et al. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain–Barré syndrome. J Neuroimmunol 2008; 202: 172-82.

  14. Asbury A. New concepts of Guillain-Barré syndrome. J Child Neurol 2000; 15: 183-91.

  15. Asbury A, Cornblath D. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990; 27(Suppl.): S21.

  16. Caballero H, Zelaya R. Variante más frecuente de Guillain Barré y su correlación con la severidad y funcionalidad en pacientes menores de 18 años del Hospital Escuela. Rev Med UNAH 2008; 11: 150-6.

  17. Piñol G, Larrodé P, Garcés M, De la Puerta I, Íñiguez C. Características del síndrome de Guillain-Barré en el área III de salud de la Comunidad Autónoma de Aragón. 2008. An Med Interna 2008; 25: 108-12.

  18. Hadden R, Comblath D, Hughes R. Electrophysiological classification of Guillain-Barré Syndrome: clinical association and outcome. Ann Neurol 1998; 44: 780-8.

  19. Alam TA, Chaundry V, Cornblath D. Electrophysiologic studies in the Guillain-Barré syndrome: Distinguishing subtypes by published criteria. Muscle Nerve 1998; 21: 1275-9.

  20. Calleja J, De Pablos C, García A. Estudio electrofisiológico en la fase inicial del síndrome de Guillain-Barré. Rev Neurol 2000; 30: 514-19.

  21. Vriensendrop F, Misho B, Blaser M, Korki C. Serum antibodies to GM1, GD1b, peripheral nerve myelin, and campylobacter jejuni in patient with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol 1999; 34: 130-5.

  22. Díaz G, Santana J, Cuó M. Consideraciones sobre el síndrome de Guillain-Barré. Revisión bibliográfica. Rev Cubana Med Gen Integr 1994; 10: 361-70.

  23. Palacios E. Síndrome de Guillaín-Barré: aspectos epidemiológicos: nuevas posibilidades terapéuticas (editorial). Acta Med Colomb 1998; 18: 236-6.

  24. Van Doorn A, Liselotte R, Jacobs B. Clinical features, pathogenesis, and treatment of Guillain-Barré Syndrome. The Lancet Neurology 2008; 7: 939-50.

  25. Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barré syndrome and Fisher syndrome: Mini-review. J Neuroimmunol 2010.

  26. Fernández J, De Rojas J, Núñez M, Miralles E, Bravo M. Síndrome de Guillain-Barré en Unidad de Cuidados Intensivos. Rev Neurol 2001; 33: 318-25.

  27. Usuki S, Taguchi K, Thompson S, Chapman P, Yu R. Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: Use relevant to Guillain-Barré syndrome. J Neurosci Res 2010.

  28. Tellería A, Calzada D. Síndrome de Guillain-Barré. Rev Neurol 2002; 34: 966-76.

  29. Sánchez D, Busquet M, Viqueira O y Fernández R. Síndrome de Guillain- Barré: Patogenia, diagnóstico y cuidados críticos en pediatría. Rev Cubana Pediatr 2001; 73: 95-105.

  30. Cerisola A, Capote G, Scavone C. Síndrome de Guillain-Barré en pediatría. Diferentes formas de presentación y dificultades en el diagnóstico precoz. Rev Neurol 2007; 44: 725-32.




2020     |     www.medigraphic.com